Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ
Symbol
Exchange
Currency
JAZZNASDAQUSD
J7ZFrankfurtEUR
Currency in USD
Disclaimer
110.01
+0.72(+0.66%)
Closed
After Hours
109.71-0.30(-0.27%)

JAZZ Comments

avadel going to destroy number 1 products sales in less than 6 months.
do the research you'll see for yourself
FDA Approves Component of Treatment Regimen for Most Common Childhood Cancerhttps://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Take into account the risks, page 44 of th eannual report: ""However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. ""
PharmaMar's antiviral is 100 times more effective against Covid-19 than other treatments, reducing its viral load by almost 100%
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
on so ii would need samples plenty and ill make my rounds
I see it as a very good stock and see very good income statements but don't know the company.. any downsides about it ?
Buying now
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.